GOG 0218 PDF


GOG randomized, double-blind, placebo-controlled phase III trial: (A) study design; (B) progression-free survival analysis (reproduced with permission) Download scientific diagram | Design of Study GOG from publication: Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes–The. ASCO Annual Meeting CHICAGO — The addition of bevacizumab as maintenance therapy to first-line treatment with standard.

Author: Meztijora Gujar
Country: Seychelles
Language: English (Spanish)
Genre: Music
Published (Last): 27 March 2004
Pages: 496
PDF File Size: 7.32 Mb
ePub File Size: 18.82 Mb
ISBN: 335-6-28021-996-3
Downloads: 30042
Price: Free* [*Free Regsitration Required]
Uploader: Akinoshura

Do not administer Avastin for at least 28 days after surgery and until the wound is fully healed Discontinue in patients with wound healing complications requiring medical intervention Hemorrhage Severe or fatal hemorrhage have occurred Do not administer Avastin to patients with serious hemorrhage or recent history of hemoptysis Discontinue for Grade hemorrhage. Analysis not designed to evaluate statistical significance between treatment arms or compare among the 3 chemotherapy cohorts.

Overview of proposed MOA of Avastin. Efficacy data overview [1]. The information contained in this section of gkg site is intended for U.

Bevacizumab Approved by FDA to Treat Ovarian Cancer Following Surgery

The safety data was consistent with the known safety profile established in first- and second-line MCRC 5. Your email has been sent! Upon completion of indicated cycles of combination therapy, Avastin is indicated for continued use as glg single agent until disease progression in patients with platinum-sensitive recurrent ovarian cancer.

The GOG study evaluated Avastin plus chemotherapy vs chemotherapy alone in platinum-sensitive ovarian cancer [ 1,3 ]. Prescribing Information Register for Updates References. Efficacy Data Recurrent Glioblastoma Studies. Thanks for sharing this page. Pregnancy warning Based on the mechanism of action and 021 studies, Avastin may cause fetal harm Advise female patients that Avastin may cause fetal harm, and to inform their healthcare provider of a known or suspected pregnancy Advise females of reproductive potential to use effective contraception during treatment with Avastin and for 6 months after the last dose of Avastin Advise nursing women that breastfeeding is not recommended during treatment with 018 and for 6 months following their last dose of treatment Avastin may impair fertility.


Recurrent Glioblastoma GBM Avastin is indicated for the treatment of recurrent 018 in adults.

OS results in patients with psOC who have not received more than 1 prior chemotherapy glg [ 1 ] Median overall survival OS: Efficacy data overview [ 1 ]. PFS data are based on investigator assessment. Study design and patient population [ 1,54 ]. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer rOC Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with gkg recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.

Recommended dosing for approved cancer types. You may also report side effects to Genentech at Median OS by chemotherapy cohort.

Metastatic renal cell carcinoma mRCC Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma. The GOG study included a diverse population of women [ 1 ]. Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Avastin-containing gob.

The number of patients with measurable disease at baseline was in the Avastin plus chemotherapy arm and in the chemotherapy alone arm Median OS: In patients receiving Avastin with lomustine, the adverse reaction profile was similar to that observed in other approved indications.


Avastin® (bevacizumab) Efficacy | Stage III or IV Ovarian Cancer & psOC, prOC

Additional serious adverse events Additional serious and sometimes fatal adverse events with increased incidence in the Avastin-treated arm vs chemotherapy arm included: Median progression-free survival PFS: Do not administer Avastin for at least 28 days after surgery and until the wound is fully healed Discontinue in patients with wound healing complications requiring medical intervention Hemorrhage Severe or fatal hemorrhage, including hemoptysis, GI bleeding, hematemesis, central nervous system hemorrhage, epistaxis, and vaginal bleeding, occurred up to 5-fold more frequently in patients receiving Avastin.

These data are likely to underestimate the true adverse event rates due to the reporting mechanisms used in this study. Avastin is not indicated for adjuvant treatment of colon cancer. Dosing and Usage Doses and Duration. Cohort analysis was exploratory. Objective response rate ORR: Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.